uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Postmenopausal craniofacial hyperhidrosis treated with botulinum toxin type B
Hidrosis Clin, Warfvinges Vag 35, SE-11251 Stockholm, Sweden.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Dermatology and Venereology. Hidrosis Clin, Warfvinges Vag 35, SE-11251 Stockholm, Sweden.
Hidrosis Clin, Warfvinges Vag 35, SE-11251 Stockholm, Sweden.
2019 (English)In: Journal of dermatology (Print), ISSN 0385-2407, E-ISSN 1346-8138, Vol. 46, no 10, p. 874-878Article in journal (Refereed) Published
Abstract [en]

Hyperhidrosis can seriously impair patients' quality of life. Medical history, including heredity and hyperhidrosis during youth, as well as current age and time elapsed since menopause, is important to consider when distinguishing between postmenopausal hyperhidrosis and vasomotor symptoms to enable adequate treatment. This report concerns a subgroup of eight postmenopausal patients participating in a randomized controlled trial regarding botulinum toxin (Btx) type B treatment in craniofacial hyperhidrosis. Even though the sample size is small and the enrolment is not yet completed, the promising data collected hitherto are interesting to present in advance because this subtype of craniofacial hyperhidrosis is often underrecognized and challenging to treat. Patients were randomized to receive Btx type B or placebo. Measurements were performed before treatment and 3 +/- 1 weeks after. The Dermatology Life Quality Index (DLQI) score was improved for all patients after Btx type B treatment (n = 3) with a median decrease of 9 points (90% median improvement). The placebo group (n = 5) had a median increase of 2 points (-18% median decline). When the same group (n = 5) received Btx type B (open) the DLQI score decreased with a median of 7 points compared with baseline (91% median improvement). Treatment-related adverse events were temporary and did not prevent improvement of life quality. Furthermore, background data evaluation uncovered interesting findings regarding vasomotor symptoms in relation to postmenopausal hyperhidrosis. In conclusion, the results indicated that Btx type B seems to be a safe and effective treatment in postmenopausal craniofacial hyperhidrosis. Further research is encouraged.

Place, publisher, year, edition, pages
WILEY , 2019. Vol. 46, no 10, p. 874-878
Keywords [en]
botulinum toxin, hyperhidrosis, NeuroBloc, postmenopause, sweating
National Category
Dermatology and Venereal Diseases
Identifiers
URN: urn:nbn:se:uu:diva-395722DOI: 10.1111/1346-8138.15029ISI: 000488392500039PubMedID: 31373068OAI: oai:DiVA.org:uu-395722DiVA, id: diva2:1365354
Available from: 2019-10-24 Created: 2019-10-24 Last updated: 2019-10-24Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records BETA

Swartling, Carl

Search in DiVA

By author/editor
Swartling, Carl
By organisation
Dermatology and Venereology
In the same journal
Journal of dermatology (Print)
Dermatology and Venereal Diseases

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 35 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf